- Home
- LIXT vs LRE Comparison
LIXT vs LRE Comparison
Compare LIXT & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- LRE
- Stock Information
- Founded
- LIXT 2005
- LRE 2001
- Country
- LIXT United States
- LRE Japan
- Employees
- LIXT N/A
- LRE N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- LRE
- Sector
- LIXT Health Care
- LRE
- Exchange
- LIXT Nasdaq
- LRE Nasdaq
- Market Cap
- LIXT 20.5M
- LRE 20.5M
- IPO Year
- LIXT N/A
- LRE 2023
- Fundamental
- Price
- LIXT $4.20
- LRE $1.51
- Analyst Decision
- LIXT
- LRE
- Analyst Count
- LIXT 0
- LRE 0
- Target Price
- LIXT N/A
- LRE N/A
- AVG Volume (30 Days)
- LIXT 120.3K
- LRE 131.7K
- Earning Date
- LIXT 11-07-2025
- LRE 07-30-2015
- Dividend Yield
- LIXT N/A
- LRE N/A
- EPS Growth
- LIXT N/A
- LRE N/A
- EPS
- LIXT N/A
- LRE N/A
- Revenue
- LIXT N/A
- LRE $110,330,328.00
- Revenue This Year
- LIXT N/A
- LRE N/A
- Revenue Next Year
- LIXT N/A
- LRE N/A
- P/E Ratio
- LIXT N/A
- LRE N/A
- Revenue Growth
- LIXT N/A
- LRE 3.92
- 52 Week Low
- LIXT $0.64
- LRE $1.00
- 52 Week High
- LIXT $6.26
- LRE $2.97
- Technical
- Relative Strength Index (RSI)
- LIXT 41.38
- LRE 46.71
- Support Level
- LIXT $4.05
- LRE $1.55
- Resistance Level
- LIXT $4.51
- LRE $1.77
- Average True Range (ATR)
- LIXT 0.34
- LRE 0.18
- MACD
- LIXT -0.02
- LRE 0.00
- Stochastic Oscillator
- LIXT 27.27
- LRE 35.17
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.